Increased live birth rate with dydrogesterone among patients with recurrent pregnancy loss regardless of other treatments

• Asher Bashiri
• Galperin G.
• Zeadna А.
• Baumfeld Ya.
• Wainstock Т.

Abstract

Background. Recurrent pregnancy loss (RPL) is defined as the loss of two or more pregnancies. Several treatment options are available, including progesterone, which is one of the few treatments that improve live birth rates in RPL patients.

Aim – to compare the live birth rates, medical and obstetric characteristics, and RPL evaluation results of women with and without progesterone treatment. These women attended the RPL clinic at Soroka University Medical Center.

Methods. A retrospective cohort study based on 866 patients was conducted. The patients were divided into two groups and examined: the dydrogesterone treatment group consisting of 509 women and a group of 357 patients who did not receive the treatment. All the patients had a subsequent (index) pregnancy.

Results. The two groups were not statistically different in terms of their demographic and clinical characteristics or evaluation results. In a univariate analysis, no statistically significant differences were found between the groups in terms of live birth rates (80.6% vs 84%; p=0.209). In a multivariate logistic analysis adjusted for maternal age, the ratio of pregnancy losses to the number of pregnancies, other administered treatments, antiphospholipid syndrome, and body mass index, dydrogesterone treatment was found to be independently associated with a higher rate of live births than the control group (adjusted OR = 1.592; CI 95% 1.051–2.413; p=0.028).

Conclusion. Progesterone treatment is associated with an increased live birth rate in RPL patients. Studies with larger sample sizes are recommended to strengthen these results.

Keywords:recurrent pregnancy loss; recurrent miscarriage; progesterone; dydrogesterone; progestins; progestogens; live birth

References

1. Mehta S., Gupta B. Recurrent Pregnancy Loss. Singapore: Springer, 2018.

2. Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril. 2012; 98: 1103–11.

3. Eshre Guideline Group on RPL; Bender Atik R., Christiansen O.B., Elson J., Kolte A.M., Lewis S., Middeldorp S., et al. ESHRE guideline: recurrent pregnancy loss. Hum Reprod Open. 2018; 2: 1–12.

4. Lachmi-Epstein A., Mazor M., Bashiri A. Psychological and mental aspects and «tender loving care» among women with recurrent pregnancy losses. Harefuah. 2012; 151: 633–37.

5. Rasmark Roepke E., Hellgren M., Hjertberg R., Blomqvist L., Matthiesen L., Henic E., et al. Treatment efficacy for idiopathic recurrent pregnancy loss – a systematic review and meta-analyses. Acta Obstet Gynecol Scand. 2018; 97: 921–41.

6. Szekeres-Bartho J., Balasch J. Progestagen therapy for recurrent miscarriage. Hum Reprod Update. 2008; 14: 27–35.

7. Shah D., Nagarajan N. Luteal insufficiency in first trimester. Indian J Endocrinol Metab. 2013; 17: 44–9.

8. Di Renzo G.C., Giardina I., Clerici G., Brillo E., Gerli S. Progesterone in normal and pathological pregnancy. Horm Mol Biol Clin Investig. 2016; 27: 35–48.

9. El-Zibdeh M.Y. Dydrogesterone in the reduction of recurrent spontaneous abortion. J Steroid Biochem Mol Biol. 2005; 97: 431–4.

10. Kumar A., Begum N., Prasad S., Aggarwal S., Sharma S. RETRACTED: oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial. Fertil Steril. 2014; 102 (5): 1357–63.e3. DOI: https://doi.org/10.1016/j.fertnstert.2014.07.1251

11. Mirza F.G., Patki A., Pexman-Fieth C. Dydrogesterone use in early pregnancy. Gynecol Endocrinol. 2016; 32: 97–106.

12. Saccone G., Schoen C., Franasiak J.M., Scott R.T. Jr, Berghella V. Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage: a systematic review and meta-analysis of randomized, controlled trials. Fertil Steril. 2017; 107: 430–8.e3.

13. Haas D.M., Ramsey P.S. Progestogen for preventing miscarriage. Cochrane Database Syst Rev. 2013; 31: CD003511.

14. Coomarasamy A., Williams H., Truchanowicz E., Seed P.T., Small R., Quenby S., et al. A randomized trial of progesterone in women with recurrent miscarriages. N Engl J Med. 2015; 373: 2141–8.

15. Druckmann R., Druckmann M.A. Progesterone and the immunology of pregnancy. J Steroid Biochem Mol Biol. 2005; 97: 389–96.

16. Bashiri A., Harlev A., Agarwal A. Recurrent Pregnancy Loss: Evidence-Based Evaluation, Diagnosis and Treatment. Cham: Springer International Publishing, 2016.

17. Jaslow C.R., Carney J.L., Kutteh W.H. Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses. Fertil Steril. 2010; 93: 1234–43.

18. Ford H.B., Schust D.J. Recurrent pregnancy loss: Etiology, diagnosis, and therapy. Rev Obstet Gynecol. 2009; 2: 76–83.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)